Conexeu Sciences Inc., a biotechnology company advancing tissue regeneration, announced it has officially commenced trading on the Nasdaq today under the ticker symbol “CNXU.” The Company currently has 25,269,996 shares on an issued and outstanding basis and 35,238,222 shares on a fully diluted basis.
The public listing, we believe, marks a significant milestone for the Company’s mission of Architecting Bioregeneration™ as we advance our regenerative tissue platform, designed to support the biological conditions necessary to restore lost or damaged tissue.
“At Conexeu, we believe regenerative medicine requires more than incremental improvement; it requires a fundamentally different foundation,” said Miles D. Harrison, President and CEO of Conexeu. “We believe we are building the biological architecture for a new generation of regenerative medicine designed not simply to replace what has been lost, but to help the body restore itself. Becoming a public company we believe strengthens our ability to continue advancing the science, infrastructure, and platform capabilities behind that long-term mission.”
Conexeu recently unveiled BIO-REGENERATIVE ERGONOMICALLY ARCHITECTED SMART TISSUE™ (B.R.E.A.S.T.™) a 3D-bioprinted regenerative breast matrix designed to support the body’s own tissue regeneration following mastectomy. Developed using Conexeu’s proprietary CXU™ platform, the matrix is intended to function as a temporary regenerative scaffold that gradually resorbs as the patient’s own tissue remodels and replaces it over time. This could represent a fundamental paradigm shift from permanent implants or traditional reconstruction approaches.
More than 100,000 women undergo mastectomies annually in the U.S., yet many elect not to pursue reconstruction, underscoring the need for additional reconstructive and regenerative options.
“Today marks an important milestone in Conexeu’s evolution as we enter the public markets during an important period of advancement across regenerative medicine, biomaterials science, and tissue restoration,” said Jeff Sharpe, Chairman of the Board of Directors. “We believe this step will enhance the Company’s ability to expand development initiatives, increase visibility within the regenerative medicine sector and continue advancing its platform across multiple potential applications.”
